Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032
New York, USA, July 31, 2025 (GLOBE NEWSWIRE) — Global Dermal Fillers Market is Predicted to Reach ~USD 12 Billion by 2032 | DelveInsight
The demand for dermal fillers is influenced by several major factors. First, the global increase in cosmetic procedures is largely driven by an aging population and a heightened desire to preserve a youthful look, coupled with growing aesthetic awareness. Additionally, there is a notable trend toward minimally invasive cosmetic treatments because they offer greater convenience, quicker recovery, and lower costs compared to traditional surgical options.
DelveInsight's Dermal Fillers Market Insights report provides the current and forecast market analysis, individual leading dermal fillers companies' market shares, challenges, dermal fillers market drivers, barriers, trends, and key market dermal fillers companies in the market.
Key Takeaways from the Dermal Fillers Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dermal fillers market during the forecast period.
In the material segment of the dermal fillers market, the hyaluronic acid (HA) category accounted for the largest market share in 2024.
Notable dermal fillers companies such as AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., and several others are currently operating in the Dermal Fillers market.
and several others are currently operating in the Dermal Fillers market. In February 2025, Crown Laboratories, Inc., a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers.
a privately held global leader in skincare innovation, announced the successful acquisition of Revance Therapeutics, Inc., a pioneering biotechnology company specializing in dermal fillers. Through this acquisition, Crown significantly enhanced its product portfolio and expanded its global presence in the dermal fillers market, particularly with RHA Redensity™ and its range of RHA® 2, RHA® 3, and RHA® 4-based dermal fillers. In October 2024, Allergan Aesthetics, an AbbVie company, announced the national availability of JUVÉDERM® VOLUMA® XC for the treatment of temple hollowing. This hyaluronic acid (HA) filler is approved for addressing moderate to severe temple hollowing in adults over 21. As the leading HA dermal filler brand preferred by both patients and providers, the JUVÉDERM® Collection of Fillers now offers the broadest range of treatment indications to help patients achieve their aesthetic goals.
To read more about the latest highlights related to the dermal fillers market, get a snapshot of the key highlights entailed in the Global Dermal Fillers Market Report
Dermal Fillers Overview
Dermal fillers are injectable substances used to restore volume, smooth out wrinkles, and enhance facial contours. Composed primarily of hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid, or polymethylmethacrylate beads, these fillers work by replenishing lost volume in the skin and stimulating collagen production. They are commonly used to treat areas such as the cheeks, lips, nasolabial folds, and under-eye hollows, providing a non-surgical alternative for facial rejuvenation. The effects of dermal fillers are temporary, lasting anywhere from six months to two years, depending on the type of filler and individual patient factors.
The procedure is minimally invasive, typically performed in a clinical setting with little to no downtime. Local anesthesia or numbing agents may be applied to minimize discomfort during injection. While generally safe when administered by trained professionals, dermal fillers can have side effects, including swelling, bruising, redness, and in rare cases, complications like vascular occlusion or infection. Due to these risks, proper patient assessment and adherence to safety protocols are essential. Increasingly popular for their convenience and effectiveness, dermal fillers remain a leading option in cosmetic dermatology for individuals seeking subtle yet noticeable aesthetic improvements.
Dermal Fillers Market Insights
North America is expected to dominate the dermal fillers market in the coming years, supported by several critical factors. This leadership is largely driven by the growing number of cosmetic procedures, which are influenced by an aging population and a strong desire to maintain youthful looks. Additionally, the preference for minimally invasive aesthetic treatments, combined with a robust healthcare infrastructure, has accelerated market expansion. Rising awareness and widespread acceptance of cosmetic enhancements further reinforce this trend. Moreover, frequent product approvals and new launches from leading players continue to strengthen North America's market position. These dynamics are anticipated to maintain the region's dominance throughout the forecast period of 2025–2032.
A key growth driver in the region is the increasing volume of aesthetic procedures, reflecting the rising demand for non-surgical treatments that deliver quick results with minimal recovery time. This surge is fueled by greater awareness, societal acceptance of cosmetic improvements, and a growing elderly population seeking effective anti-aging solutions.
In addition, major industry players are actively investing in R&D to develop advanced dermal filler products tailored for regional needs. For instance, in June 2023, Galderma received FDA approval for Restylane® Eyelight, specifically designed to treat under-eye hollows in adults over 21. It is the first and only HA filler in the U.S. featuring NASHA® Technology to restore under-eye volume and deliver natural results.
Similarly, in February 2022, Allergan Aesthetics, an AbbVie company, secured FDA approval for JUVÉDERM® VOLBELLA® XC for treating infraorbital hollows in adults over 21. This product also serves as a lip augmentation solution and helps correct perioral lines, enhancing overall facial aesthetics. Together, the growing demand for cosmetic procedures and strategic product innovations are fueling the dermal fillers market in North America, solidifying its status as a leading region in the global market.
To know more about why North America is leading the market growth in the dermal fillers market, get a snapshot of the Dermal Fillers Market Outlook
Dermal Fillers Market Dynamics
The dermal fillers market is experiencing significant growth, driven primarily by the increasing demand for minimally invasive aesthetic procedures. Rising awareness about cosmetic enhancements and the desire for youthful appearances have fueled the adoption of dermal fillers across various demographics. Factors such as the aging global population, especially in developed economies, and growing disposable incomes in emerging markets have further contributed to market expansion. These procedures are preferred for their relatively quick recovery time and non-surgical nature, which aligns with the current trend toward less invasive treatment options.
Technological advancements in dermal filler products have also played a crucial role in shaping market dynamics. Innovations in filler composition, including the introduction of hyaluronic acid-based and biostimulatory fillers, have improved safety profiles, longevity, and natural results. Moreover, ongoing research and development efforts by key players to develop fillers with longer-lasting effects and fewer side effects continue to enhance product appeal. These advancements have not only expanded the scope of applications but have also increased patient satisfaction, encouraging repeat procedures and contributing to market growth.
Regulatory approvals and favorable reimbursement policies in certain regions further support the expansion of the dermal fillers market. However, stringent regulations in countries with established healthcare systems can act as barriers for new entrants. Additionally, the rise of medical tourism in countries like Thailand, India, and Mexico has created new growth opportunities for service providers and manufacturers, as patients seek affordable yet high-quality aesthetic treatments.
Despite these positive trends, the dermal fillers market faces challenges such as the risk of complications, including allergic reactions and improper injections leading to vascular occlusion. Additionally, the availability of counterfeit or substandard products in some markets poses safety concerns and threatens consumer confidence. Competition from alternative aesthetic procedures like botulinum toxin injections and energy-based devices also adds pressure to the market. Nevertheless, continuous innovation, increasing social acceptance, and the growing influence of social media on beauty standards are expected to sustain robust growth in the coming years.
Get a sneak peek at the dermal fillers market dynamics @ Dermal Fillers Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dermal Fillers Market CAGR ~8% Dermal Fillers Market Size by 2032 ~USD 12 Billion Key Dermal Fillers Companies AbbVie Inc., Galderma, Merz Pharma, Tiger BioSciences, Teoxane SA, Crown Laboratories, Inc., Prollenium Medical Technologies, Inc., Johnson & Johnson Services, Inc., Anika Therapeutics, Inc., Fillmed, VIVACY Laboratories, Sinclair, Medytox, HUGEL, Inc., Ipsen Pharma, Evolus, Inc., Symatese, LG Chem, KORU Pharma Co., LTD., BIOPLUS CO., LTD., among others
Dermal Fillers Market Assessment Dermal Fillers Market Segmentation Dermal Fillers Market Segmentation By Product Type: Biodegradable Fillers and Non-Biodegradable Fillers Dermal Fillers Market Segmentation By Route of Material: Hyaluronic Acid (HA), Calcium hydroxylapatite (CaHA), Poly-L-lactic acid (PLLA), Polymethylmethacrylate (PMMA), and Others Dermal Fillers Market Segmentation By Route of Gender: Male and Female Dermal Fillers Market Segmentation By End-User: Hospitals, Dermatology Clinics, and Others Dermal Fillers Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the dermal fillers market are set to emerge as the trendsetter explore @ Dermal Fillers Analysis
Table of Contents 1 Dermal Fillers Market Report Introduction 2 Dermal Fillers Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dermal Fillers Market Key Factors Analysis 6 Dermal Fillers Market Porter's Five Forces Analysis 7 Dermal Fillers Market Layout 8 Dermal Fillers Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us
Interested in knowing the dermal fillers market by 2032? Click to get a snapshot of the Dermal Fillers Market Analysis
Related Reports
Aesthetic Implants Market
Aesthetic Implants Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic implants companies, including POLYTECH Health & Aesthetics GmbH, Sientra, Inc, Surgiform Innovative Surgical Products, GC Aesthetics, Dentsply Sirona, Institut Straumann AG, AVINENT, AbbVie, Establishment Labs S.A., Mentor (Johnson & Johnson Medical Ltd), 3M, Zimmer Biomet, Alpha Aesthetics, Symatese, Integra LifeSciences, Sebbin, IDEAL IMPLANT INCORPORATED, Lattice Medical, CEREPLAS, Guangzhou Wanhe Plastic Material Co Ltd, among others.
Medical Aesthetic Devices Market
Medical Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key medical aesthetic devices companies, including Johnson & Johnson, HansBioMed., AbbVie Inc., Sebbin, Sientra, Inc., POLYTECH Health & Aesthetics GmbH, Suneva Medical, Hanson Medical Inc., SurgiSil, Surgiform Technologies LLC, Alma Lasers, Candela Medical., Lumenis., Cutera., Sciton Inc, Merz Pharma GmbH & Co.KGaA, Bausch Health Companies Inc., Venus Concept., TRIA BEAUTY, Cynosure Inc., GALDERMA, among others.
Aesthetic Thread Market
Aesthetic Thread Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key aesthetic thread companies, including Aptos International Ltd, Intraline, Healux Corporation, Croma Pharma GambH, Les Encres Cosmetic Threads, W & O Medical Esthetics Gmbh, Hyundae Meditechh Co. Ltd., N-Finders Co., Ltd., Nova Threads, Savia medical, Metro Korea Co., Ltd., RIVER AESTHETICS, Spring Thread, RELIFE S.r.l., Sinclair, MINT™, PDO MAX, Promoitalia, EWELL Medical., illari Threads, among others.
Aesthetic Lasers Market
Aesthetic Lasers Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key aesthetic lasers companies, including Boston Scientific Corporation, Candela Medical, Lynton Lasers, Lutronic, Fotona, Alma Lasers, Sciton, Astanza Laser, Konmison, AMI INC., Lumibird Medical (Ellex), Cutera, biolitec® Holding GmbH & Co KG, Cartessa Aesthetics, Beagle E-Comm Private Limited, WON TECH Co., Ltd., Attikouris Enterprises Ltd., Aftab Forouzan Aria Company, SL LASERS, Reveal Lasers LLC, among others.
Energy-Based Aesthetic Devices Market
Energy-Based Aesthetic Devices Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key energy-based aesthetic devices companies, including Alma Lasers, Candela Medical, Lumenis, Cutera, Hologic Inc., Sciton Inc., Merz Pharma GmbH & Co.KGaA, Bausch Health Companies Inc., Venus Concept, TRIA BEAUTY, Cynosure Inc., SharpLight Technologies Inc., Lutronic, Fotona, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
3 hours ago
- Chicago Tribune
Aurora considers new $4 million public safety dispatch, records software
The city of Aurora is considering buying new dispatch and records management software for its public safety departments for just over $4 million. Through the proposed five-year contract with Mark43, Inc. of New York, Aurora would be replacing its Computer Aided Dispatch system used by both the fire and police departments as well as its Records Management System used just by the police. The $4.02 million price tag includes replacements for both systems as well as any work needed to interface the new software with others the city has. That's according to Aurora Police Cmdr. Bryan Handell, who presented the proposal to the Aurora City Council's Information and Technology Committee late last month. The proposal was unanimously recommended for approval by the committee, so now it is set to go before the Committee of the Whole on Tuesday. During his presentation, Handell called the software 'probably the most vital system for public safety.' The Computer Aided Dispatch system, also called CAD, is used to dispatch and track calls for service not only for Aurora's police and fire departments but also for the North Aurora Police Department and the Fox Valley Park District Police Department, according to Handell's presentation. He said that police officers and firefighters use a mobile version to get those calls for service plus see additional information such as notes taken by the dispatcher and location data. The other part of the software, the Records Management System, or RMS, is just for the police department, Handell said. The police and fire departments' records systems need to be kept separate, he said, because they each contain different types of sensitive information. Aurora's current CAD and police RMS systems are from Hexagon, but that software is at the end of its life and will no longer be supported in the near future because the company is looking for its customers to buy its latest software instead, according to Handell. Plus, he said many of the features promised in the initial contract with Hexagon were never provided or did not work to the city's standards. A survey of police employees also showed that nearly 80% of those who responded were 'very or somewhat dissatisfied' with the system, over 85% wanted the department to look at other options and over 30% could not find one thing they liked about the current system, Handell's presentation showed. 'Officers have to use this daily for responding to calls, writing reports, and it's not something that they enjoy using,' he said. 'It's not making their job easier.' Over the past 10 years of using the software, the city has spent around $8 million on it, which includes a $5 million initial purchase price, according to Handell. Since the city would have to buy new software even if it stayed with Hexagon, and since 'we're already unhappy' with that company, 'why would we re-sign with them?' Handell asked. Instead, 'let's see what the market has to offer,' he said. The city asked for proposals for new CAD and RMS systems in 2024, and 10 companies responded — but not Hexagon, according to Handell. He said those 10 companies were eventually narrowed down to just two options through multiple rounds of demos, and using Mark43 for both CAD and RMS stood out as both the better and least-expensive option. In addition to its 'significantly-lower price' as compared to the other option, Mark43's offerings had a modern, user-friendly design and a seamless integration between CAD and RMS, which may have been more difficult with the other option since it would involve buying the CAD and RMS systems from two different companies, Handell said. Plus, with just one vendor instead of two, updates and maintenance to the software would be easier, not causing potential integration issues like if the two systems were from different companies, he said. Unlike Hexagon, Mark43 is focused just on public safety software, according to Handell. Other departments across the country are using the company, too, including in places like Washington, D.C., and Seattle, Washington, his presentation showed. The proposed five-year contract with Mark43 for its software is fully funded, he said, through budgeted IT funds as well as 911 surcharge funds and police asset forfeiture funds. If the proposal passes through the Committee of the Whole on Tuesday, it will then go before the Aurora City Council for final approval. The next City Council meeting is on Aug. 12. If the contract is approved, then starts the 'lengthy process' of converting data and implementing the new software, according to a staff report about the proposal included with the upcoming Committee of the Whole agenda on the city's website. While that integration process is going on, public safety staff still need to use the current software, the report said. So, later this year staff are expected to ask City Council to extend the city's maintenance and licensing agreement with Hexagon.
Business Insider
3 hours ago
- Business Insider
Siebert Williams Shank & Co Sticks to Its Buy Rating for Infinity Natural Resources, Inc. Class A (INR)
In a report released today, Gabriele Sorbara from Siebert Williams Shank & Co maintained a Buy rating on Infinity Natural Resources, Inc. Class A, with a price target of $26.00. The company's shares closed yesterday at $15.07. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Sorbara is a 5-star analyst with an average return of 23.2% and a 57.26% success rate. Sorbara covers the Energy sector, focusing on stocks such as EOG Resources, Comstock Resources, and Civitas Resources. Currently, the analyst consensus on Infinity Natural Resources, Inc. Class A is a Strong Buy with an average price target of $25.75, which is a 70.87% upside from current levels. In a report released on July 14, KeyBanc also maintained a Buy rating on the stock with a $24.00 price target. Based on Infinity Natural Resources, Inc. Class A's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $15.39 billion and a net profit of $4.37 billion. In comparison, last year the company earned a revenue of $71.76 million and had a net profit of $60.23 million
Business Insider
3 hours ago
- Business Insider
Infinity Natural Resources, Inc. Class A (INR) Gets a Buy from Siebert Williams Shank & Co
In a report released on July 11, Gabriele Sorbara from Siebert Williams Shank & Co maintained a Buy rating on Infinity Natural Resources, Inc. Class A, with a price target of $26.00. The company's shares closed last Friday at $15.25. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Sorbara is a 5-star analyst with an average return of 21.0% and a 57.02% success rate. Sorbara covers the Energy sector, focusing on stocks such as Civitas Resources, Comstock Resources, and EOG Resources. Infinity Natural Resources, Inc. Class A has an analyst consensus of Strong Buy, with a price target consensus of $25.75, which is a 68.85% upside from current levels. In a report released today, KeyBanc also maintained a Buy rating on the stock with a $24.00 price target. The company has a one-year high of $23.00 and a one-year low of $13.64. Currently, Infinity Natural Resources, Inc. Class A has an average volume of 284.1K.
